Arno Therapeutics, Inc., a clinical stage biopharmaceutical company, is developing innovative products for the treatment of cancer. Arno has exclusive worldwide rights to develop and market three innovative anti-cancer product candidates. These compounds are in clinical or preclinical development as product candidates to treat hematologic malignancies and solid tumors. For more information, visit the company’s website at www.arnothera.com.
Arno Therapeutics, Inc. (ARNI) Starts Presentation at LD Micro Conference
Previous Article
Next Article
Search Articles
Latest Articles
- MissionIRNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Rises as Key Player in Critical Materials with RapidSX(TM)
- MissionIRNewsBreaks – Massimo Group (NASDAQ: MAMO) Unveils 2026 T-Boss 900L Crew Utility Vehicle
- New Pacific Metals Corp. (NYSE American: NEWP) (TSX: NUAG) Opens Rare Frontier in Bolivia’s Underexplored Silver Belt
- MissionIRNewsBreaks – PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) Secures $1.74 Million in Funding for Three Nova Scotia Community Solar Projects
- Lantern Pharma Inc. (NASDAQ: LTRN) Releases Latest AI Breakthrough for Central Nervous System (‘CNS’) Drug Development with predictBBB.ai (TM): A High-Accuracy Open-Access AI Drug Development Tool